Johannes C.M. van der Loo, PhD
Adjunct Associate Professor of Pathology and Laboratory Medicine
Department: Pathology and Laboratory Medicine
Contact information
Children's Hospital of Philadelphia
Raymond G. Perelman Center For Cellular & Molecular Therapeutics
Colket Translational Research Building, Room 5054
3501 Civic Center Boulevard
Philadelphia, PA 19104
Raymond G. Perelman Center For Cellular & Molecular Therapeutics
Colket Translational Research Building, Room 5054
3501 Civic Center Boulevard
Philadelphia, PA 19104
Office: (267) 425-2011
Lab: (513) 254-1568 Mobile
Lab: (513) 254-1568 Mobile
Email:
vanderlooj@chop.edu
vanderlooj@chop.edu
Publications
Education:
BA (Biology)
State University Utrecht, Netherlands, 1983.
MA (Medical Biology)
State University Utrecht, Netherlands, 1987.
Teaching (Biology)
State University Utrecht, Netherlands, 1989.
PhD (Cell Biology)
Erasmus University, Rotterdam, Netherlands, 1995.
Permanent linkBA (Biology)
State University Utrecht, Netherlands, 1983.
MA (Medical Biology)
State University Utrecht, Netherlands, 1987.
Teaching (Biology)
State University Utrecht, Netherlands, 1989.
PhD (Cell Biology)
Erasmus University, Rotterdam, Netherlands, 1995.
Description of Other Expertise
Design, Commissioning and Qualification of cleanrooms for Aseptic Manufacturing of Viral Vectors in compliance with US and EU cGMP requirementsDescription of Research Expertise
Manufacturing of pre-clinical and GMP-grade Adeno-Associated Virus (AAV) and Lentivirus-based vectors in support of Pharmacology/Toxicology studies and Early Phase Clinical Trials.Selected Publications
Smith RH, Bloomer H, Fink D, Keyvanfar K, Nasimuzzaman M, Sancheznieto F, Dutta R, Guenther Bui K, Alvarado LJ, Bauer TR Jr, Hickstein DD, Russell DW, Malik P, van der Loo JCM, Highfill SL, Kuhns DB, Pirooznia M, Larochelle A.: Preclinical Evaluation of Foamy Virus Vector-Mediated Gene Addition in Human Hematopoietic Stem/Progenitor Cells for Correction of Leukocyte Adhesion Deficiency Type 1. Hum Gene Ther. 33(23-24): 1293-1304, December 2022.SAKSHI ARORA, Amber Vu, Katarina Kulhankova, Matthew Weaver, Katherine Excoffon, Xueyuan Liu, Johannes C. Van Der Loo, Paul B. McCray, Beverly L. Davidson: Development of a Stable Cell Line and Downstream Process for Improved Titer of GP64-pseudotyped Lentivirus Particles. Presentation, 25th Annual Meeting of the American Society of Gene & Cell Therapy, Washington, DC May 2022.
Nasimuzzaman M, Villaveces S, van der Loo JCM, Alla S. : Process Development for the Production and Purification of Adeno-Associated Virus (AAV)2 Vector using Baculovirus-Insect Cell Culture System. J Vis Exp. Jan 13(179), January 2022.
Timmins L, Burr A, Carrol K, Keefe R, Teryek M, Cantolupo L, van der Loo JCM, Heathman T, Gormley A, Smith D, Parekkadan B: Selecting a cell engineering methodology during cell therapy product development. Cell Transplantation 30: 1-17, April 2021.
Kuzmin DA, Shutova MV, Johnston NR, Smith OP, Fedorin VV, Kukushkin YS, van der Loo JCM, Johnstone EC: The clinical landscape for AAV gene therapies. Nature Reviews Drug Discovery 20: 173-174, Jan 2021.
Nasimuzzaman M, van der Loo JCM, Malik P.: Production and Purification of Baculovirus for Gene Therapy Application. J Vis Exp. Apr 9(134), April 2018.
Goodman MA, Arumugam PI, Pillis DM, Nasimuzzaman MD, Lynn D, van der Loo JCM, Dexheimer PJ, Keddache M, Bauer Jr. TR, Hickstein DD, Russell DW, and Malik P: Foamy Virus Vector Carries a Strong Insulator in its Long Terminal Repeat Which Reduces Its Genotoxic Potential. Journal of Virology 92(1): pii: e01639-17. doi: 10.1128/JVI.01639-17, Dec 2017.
Heizel M, Suzuki T, Hashtchin AR, Arumugam P, Carey B, Schwabbauer M, Kuhn A, Meyer J, Schambach A, van der Loo J, Moritz T, Trapnell BC, Lachmann N.: Function and Safety of Lentivirus-Mediated Gene Transfer for CSF2RA-Deficiency. Human Gene Therapy Methods 28(6): 318-329, Dec 2017.
Flotte TR, Daniels E, Benson J, Bevett-Rose JM, Cornetta K, Diggins M, Johnston J, Sepelak S, van der Loo JCM, Wilson JM, McDonald CL.: The Gene Therapy Resource Program: A Decade of Dedication to Translational Research by the National Heart, Lung, and Blood Institute. Hum Gene There Clin Dev 28(4): 178-186, Dec 2017.
George LA, Sullivan SK, Giermasz A, Ducore J, Samuelson-Jones BJ, Cuker A, Sullivan LM, Majumdar S, Teitel J, McGuinn CE, Ragni MV, Luk AY, Hui D, Wright JF, Chen Y, Wachtel K, Galvao AM, Winters A, Galas T, van der Loo JCM, Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA: Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. New Engl J Med 377(23): 2215-2227, Dec 2017.